Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 196-206

  Azad, Abul Kalam ^a   Bairati, Isabelle ^c   Samson, Elodie ^c   Cheng, Dangxiao ^a   Mirshams, Maryam ^a   Qiu, Xin ^a   Savas, Sevtap ^a   Waldron, John ^b   Wang, Changshu ^d   Goldstein, David ^a   Xu, Wei ^a   Meyer, Francois ^c   Liu, Geoffrey ^a,b,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CCND1 GENE; CTLA4 GENE; CYP2D6 GENE; DISEASE FREE SURVIVAL; DNMT3B GENE; EARLY CANCER; ERCC1 GENE; ERCC2 GENE; ERCC4 GENE; ERCC5 GENE; FEMALE; FGFR4 GENE; GENE; GENE SEQUENCE; GENOTYPE; GSTM1 GENE; GSTT1 GENE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MMP3 GENE; MSH2 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TP53 GENE; XPA GENE; XRCC1 GENE; XRCC3 GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84855438473     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1759     Document Type: Article

References (49)

1. Canadian Cancer Society. Canadian Cancer Society's Steering Committee: Canadian cancer statistics, 2009; 2009 [cited 2010 Nov 25]. Available from: http://www.cancer.ca.
2. American Cancer Society. Cancer facts and figures 2009; 2009 [cited 2010 Dec 15]. Available from: http://www.cancer.org.
3. Million RR, Cassisi NJ, Clark JR. Cancer of the head and neck. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia, PA: JB Lippincott; 1989. p. 488-590.
4. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709. (Pubitemid 351671886)
5. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56. (Pubitemid 46740304)
6. Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, et al. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev 2008;17:490-9. (Pubitemid 351469197)
7. Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 2011;6:296-304.
8. Cheung WY, Liu G. Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am 2009;38:75-91, viii.
9. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004;6:109-18. (Pubitemid 38607664)
10. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005;97:481-8. (Pubitemid 40590429)
11. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 2005;23:5805-13.
12. Meyer F, Fortin A, Gelinas M, Nabid A, Brochet F, Tetu B, et al. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol 2009;27:2970-6.
13. Bairati I, Meyer F, Jobin E, Gelinas M, Fortin A, Nabid A, et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer 2006;119:2221-4. (Pubitemid 44423684)
14. deBakker PI, Burtt NP, Graham RR, Guiducci C, Yelensky R, Drake JA, et al. Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 2006;38:1298-303. (Pubitemid 44646292)
15. Wong YK, Chang KW, Cheng CY, Liu CJ. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 2006;35:51-4.
16. Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope 2005;115:2221-31. (Pubitemid 44391640)
17. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010;28:4029-37.
18. Azad AK, Bairati I, Samson E, Cheng D, Cheng L, Mirshams M, et al. Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. Cancer. 2011 Aug 25. [Epub ahead of print].
19. Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, et al. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2006;24:3483-9.
20. Khaghanzadeh N, Erfani N, Ghayumi MA, Ghaderi A. CTLA4 gene variations and haplotypes in patients with lung cancer. Cancer Genet Cytogenet 2010;196:171-4.
21. Bouwhuis MG, Gast A, Figl A, Eggermont AM, Hemminki K, Schadendorf D, et al. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother 2010;59:303-12.
22. Sun T, Zhou Y, Yang M, Hu Z, Tan W, Han X, et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008;68:7025-34.
23. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-11.
24. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001;2:145-52. (Pubitemid 33674879)
25. Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002;277:46478-86. (Pubitemid 35417644)
26. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002;54:1-8. (Pubitemid 34492947)
27. Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, Clayman GL, et al. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 1999;20:2125-9. (Pubitemid 29535314)
28. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59:2557-61. (Pubitemid 29269097)
29. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001;22:917-22. (Pubitemid 32514958)
30. Abdel-Rahman SZ, El-Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 2000;159:63-71.
31. Lei YC, Hwang SJ, Chang CC, Kuo HW, Luo JC, Chang MJ, et al. Effects on sister chromatid exchange frequency of polymorphisms in DNA repair gene XRCC1 in smokers. Mutat Res 2002;519:93-101. (Pubitemid 34874990)
32. Monaco R, Rosal R, Dolan MA, Pincus MR, Brandt-Rauf PW. Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J 2007;26:541-6. (Pubitemid 350060770)
33. Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006;66:1022-30. (Pubitemid 44633517)
34. Blons H, Gad S, Zinzindohoue F, Maniere I, Beauregard J, Tregouet D, et al. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res 2004;10:2594-9. (Pubitemid 38509131)
35. Wakasugi M, Reardon JT, Sancar A. The non-catalytic function of XPG protein during dual incision in human nucleotide excision repair. J Biol Chem 1997;272:16030-4. (Pubitemid 27265587)
36. Liu SY, Liu YC, Huang WT, Huang GC, Su HJ, Lin MH. Requirement of MMP-3 in anchorage-independent growth of oral squamous cell carcinomas. J Oral Pathol Med 2007;36:430-5.
37. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996;271:13055-60. (Pubitemid 26175880)
38. Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 2000;19:1102-13. (Pubitemid 30153797)
39. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993;365:852-5. (Pubitemid 23341030)
40. Wang F, Chang D, Hu FL, Sui H, Han B, Li DD, et al. DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev 2008;17:507-17. (Pubitemid 351469199)
41. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006;24:4333-9. (Pubitemid 46630792)
42. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7. (Pubitemid 34292555)
43. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 2005;577:275-83. (Pubitemid 41225506)
44. Chen K, Hu Z, Wang LE, Zhang W, El-Naggar AK, Sturgis EM, et al. Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:4300-5. (Pubitemid 47105994)
45. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65. (Pubitemid 36278852)
46. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002;156:300-10. (Pubitemid 34857997)
47. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
48. Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006;59:445-53.
49. Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Putter C, Wild CA, et al. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 2011;9:139.